About Us
Relationship with the National Bleeding Disorders Foundation
A Message to Donors
Investment Strategy
Investment Approach
Investment Criteria and Process
Venture Philanthropy
Ways to Give
Our Portfolio
Who We Are
News
Contact
About Us
Relationship with the National Bleeding Disorders Foundation
A Message to Donors
Investment Strategy
Investment Approach
Investment Criteria and Process
Venture Philanthropy
Ways to Give
Our Portfolio
Who We Are
News
Contact
Our Portfolio
APPROACH:
RNA-sequence target identification
STRATEGIC AREA:
ASO (Anti-sense Oligonucleotide) therapeutics for bleeding disorder
P2C FUNDING IMPACT:
Factor XI deficiency and women with Hemophilia
DATE OF INVESTMENT:
September 2023
APPROACH:
Non-invasive vagus nerve stimulation
STRATEGIC AREA:
Non-invasive medical device
P2C FUNDING IMPACT:
Von Willebrand Disease and women with Heavy Menstrual Bleeding
DATE OF INVESTMENT:
October 2023
APPROACH:
RNA-sequence target identification
STRATEGIC AREA:
ASO (Anti-sense Oligonucleotide) therapeutics for bleeding disorder
P2C FUNDING IMPACT:
Factor XI deficiency and women with Hemophilia
APPROACH:
Non-invasive vagus nerve stimulation
STRATEGIC AREA:
Non-invasive medical device
P2C FUNDING IMPACT:
Von Willebrand Disease and women with Heavy Menstrual Bleeding
